Transparency data

UK NSC agenda March 2021

Updated 20 October 2021

© Crown copyright 2021

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/uk-nsc-meeting-march-2021/uk-nsc-agenda-march-2021

1. Introduction and apologies (declarations and conflicts)

2. Minutes of the last meeting (28 October 2020)

3. Matters arising

3.1 Director’s update

  • Creation of National Institute of Health Protection
  • Screening advisory body task and finish group
  • Lung cancer
  • Roll out of non-invasive prenatal testing in the NHS Fetal Anomaly Screening Programme

3.2 Ethics and engagement

  • Ethics task group on child-parent screening for familial hypercholesterolemia
  • Ethical principles to inform the restoration of adult screening pathways in the context of COVID-19
  • Public dialogue on the implications of whole genome sequencing on newborn screening
  • UK NSC stakeholder engagement review – preliminary results

3.3 2020 annual call for topic submissions

3.4 IMDs in newborn screening

4. Adult screening

  • Adult reference group (ARG) report
  • Evidence review summary – screening for stomach cancer
  • Evidence review summary – screening for hearing loss in adults
  • Evidence review summary – screening for hereditary hemochromatosis
  • Evidence map – screening for thrombophilia in all ages

5. Fetal, maternal and child health (FMCH) screening

  • FMCH report
  • NHS FASP: programme modification
  • Evidence map – fetal presentation: 2019 annual call for topic proposal
  • Evidence map – screening for adolescent idiopathic scoliosis
  • Evidence map – screening for adrenoleukodystrophy

6. Updates (information only)

  • NIHR NETSCC

7. Any other business

Back to top